Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study
Conclusions
This pharmacovigilance study serves as a clinical reminder to physicians to be more vigilant for fluid retention-associated AEs with BCR::ABL inhibitors. (Source: BMJ Open)
Source: BMJ Open - August 3, 2023 Category: General Medicine Authors: Huang, J., Cai, J., Ye, Q., Jiang, Q., Lin, H., Wu, L. Tags: Open access, Pharmacology and therapeutics Source Type: research
Vodobatinib, a potent, orally bioavailable brain-penetrating inhibitor of c-Abl as a potential neuroprotective agent for treatment of Parkinson disease
Background:Preclinical evidence suggests that c-Abl is critical for pathogenesis of Parkinson Disease (PD). Vodobatinib is a potent, orally bioavailable inhibitor of c-Abl currently being evaluated in patients with PD in the PROSEEK clinical trial. Nilotinib, a multikinase inhibitor of c-Abl, was recently shown to be unsuccessful in slowing PD progression (Simuni et al. 2021). This failure of nilotinib at its maximally permissible dose of 300mg was attributed to insufficient brain penetration because the concentration of nilotinib in the CSF was found to be 7-fold lower than its IC50 for c-Abl. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - August 1, 2023 Category: Neurology Authors: R.R. Walsh, S.P. Piccoli, R.S. Talluri, S. Mandhane, D. Love, O. Hurko, S.-L. Yao, V. Ramanathan, N. Damle Source Type: research
Cuproptosis-related signature for clinical prognosis and immunotherapy sensitivity in hepatocellular carcinoma
ConclusionsOur findings highlight the potential of the CRGs risk score as an independent and promising biomarker for clinical prognosis and immunotherapy sensitivity in HCC patients. (Source: Journal of Cancer Research and Clinical Oncology)
Source: Journal of Cancer Research and Clinical Oncology - July 11, 2023 Category: Cancer & Oncology Source Type: research
Evaluation of chronic drug-induced electrophysiological and cytotoxic effects using human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs)
In conclusion, the evaluation of chronic drug-induced cardiotoxicity using a hiPSC-CMs in vitro assay can contribute to the early de-risking of compounds and help optimize the drug development process. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - July 10, 2023 Category: Drugs & Pharmacology Source Type: research
Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients
In this study, we show that presence of myelofibrosis (MF) at the time of diagnosis is a factor associating with TFR failure. Fibrotic transformation is governed by the action of several cytokines, and interestingly, some of them have also been described to support LSC persistence. At the cellular level, these could be produced by both malignant cells and by components of the bone marrow (BM) niche, including megakaryocytes (MKs) and mesenchymal stromal cells (MSCs). In our cohort of 57 patients, around 40% presented with MF at diagnosis and the number of blasts in the peripheral blood and BM was significantly elevated in ...
Source: Frontiers in Pharmacology - July 4, 2023 Category: Drugs & Pharmacology Source Type: research
Virtual Screening, Molecular Docking, and Dynamic Simulations Revealed TGF- β1 Potential Inhibitors to Curtail Cervical Cancer Progression
Appl Biochem Biotechnol. 2023 Jul 1. doi: 10.1007/s12010-023-04608-5. Online ahead of print.ABSTRACTCervical cancer is one of the main causes of cancer death in women globally, and its epidemiology is similar to that of a low-infectious venereal illness. Many sexual partners and early age at first intercourse have been demonstrated to have a significant influence on risk. TGF-β1 is a multifunctional cytokine that is required for cervical carcinoma metastasis, tumor development, progression, and invasion. The TGF-β1 signaling system plays a paradoxical function in cancer formation, suppressing early-stage tumor growth whi...
Source: Applied Biochemistry and Biotechnology - July 1, 2023 Category: Biochemistry Authors: Pavan Kumar Poleboyina Umakanth Naik Akbar Pasha Doneti Ravinder Shivaji Bhanothu Sneha Malleswari Poleboyina Umamaheshwari Amineni Smita C Pawar Source Type: research
Virtual Screening, Molecular Docking, and Dynamic Simulations Revealed TGF- β1 Potential Inhibitors to Curtail Cervical Cancer Progression
Appl Biochem Biotechnol. 2023 Jul 1. doi: 10.1007/s12010-023-04608-5. Online ahead of print.ABSTRACTCervical cancer is one of the main causes of cancer death in women globally, and its epidemiology is similar to that of a low-infectious venereal illness. Many sexual partners and early age at first intercourse have been demonstrated to have a significant influence on risk. TGF-β1 is a multifunctional cytokine that is required for cervical carcinoma metastasis, tumor development, progression, and invasion. The TGF-β1 signaling system plays a paradoxical function in cancer formation, suppressing early-stage tumor growth whi...
Source: Applied Biochemistry and Biotechnology - July 1, 2023 Category: Biochemistry Authors: Pavan Kumar Poleboyina Umakanth Naik Akbar Pasha Doneti Ravinder Shivaji Bhanothu Sneha Malleswari Poleboyina Umamaheshwari Amineni Smita C Pawar Source Type: research
GSE227347 Gene expression data from biological replicates of imatinib and nilotinib resistant K-562 cells.
Contributor : Meike KaehlerSeries Type : Expression profiling by arrayOrganism : Homo sapiensResistant cells were generated by stepwise exposure to increasing concentrations of imatinib or nilotinib to establish 0.5 and 2 µM imatinib and 0.05 µM nilotinib resistant cells. This procedure was performed twice independently to establish biological replicates of TKI resistance.We performed microarrays (Clariom S) to analyze the changes in gene expression during the development of TKI resistance. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - June 30, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
Cancers, Vol. 15, Pages 3384: Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment
In conclusion, myeloid mutations detectable at diagnosis increase CVE risk, particularly for patients on imatinib, and might be considered for first-line TKI choice. (Source: Cancers)
Source: Cancers - June 28, 2023 Category: Cancer & Oncology Authors: Ruth Stuckey Adri án Segura-Díaz Mar ía Nieves Sáez Perdomo Manuel Mateo P érez Encinas J óse David González San Miguel Yanira Florido Santiago S ánchez-Sosa Juan Francisco L ópez-Rodríguez Cristina Bilbao-Sieyro Mar ía Teresa Gómez-Casares Tags: Article Source Type: research
GSE230534 Expression data from MSCs of healthy donors vs. CML patients
In this study, we show that presence of myelofibrosis (MF) at the time of diagnosis is a factor that strongly associates with TFR failure. Fibrotic transformation is governed by the action of several cytokines, and interestingly, some of them have also been described to support LSC persistence. At the cellular level, these could be produced by both malignant cells and by components of the bone marrow (BM) niche, including megakaryocytes (MKs) and mesenchymal stromal cells (MSCs). In our cohort of 57 patients, around 40% presented with MF at diagnosis and the number of blasts in the peripheral blood and BM was significantly...
Source: GEO: Gene Expression Omnibus - June 23, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
Identification of a Novel Myc-Regulated Gene Signature for Patients with Kidney Renal Clear Cell Carcinoma
J Oncol. 2022 Dec 26;2022:3487859. doi: 10.1155/2022/3487859. eCollection 2022.ABSTRACTGiven that myc was known to be a cancer-causing gene in several cancers including kidney renal clear cell carcinoma (KIRC). We aimed to construct myc-regulated genes (MRGs)-based prognostic signature. We obtained the mRNA expression and clinical data of KIRC from The Cancer Genome Atlas (TCGA) database and MRGs from the Molecular Signature Database (MSigDB). Then, a prognostic signature consisting of 8 MRGs (IRF9, UBE2C, YBX3, CDKN2B, CKAP2L, CYFIP2, FBLN5, and PDLIM7) was developed by differential expression analysis, cox regression ana...
Source: Journal of Oncology - June 21, 2023 Category: Cancer & Oncology Authors: Shengqiang Fu Yifu Liu Zhicheng Zhang Ming Mei Qiang Chen Siyuan Wang Xiaorong Yang Ting Sun Ming Ma Wenjie Xie Source Type: research
